Quantitative determination of CGS 18102A, a new anxiolytic, in human plasma using capillary gas chromatography/mass spectrometry.
CGS 18102A is a novel hexahydrobenzopyranopyridine that has a mixed pharmacological profile of 5-HT-1A agonist and 5-HT-2 antagonist properties. Based upon these mechanisms, the compound is predicted to have anxiolytic efficacy with possible efficacy in depression. Preclinical studies in the rat have shown the drug to be well absorbed and extensively metabolized. Because of the anticipated low plasma levels in humans a gas chromatography/mass spectrometry (GC/MS) analytical method has been developed and validated to determine plasma concentrations of CGS 18102A in early clinical studies. The method utilizes CGS 18416A as the internal standard. Samples (1 mL) were extracted with pentane:ethyl acetate (75:25, v:v). Extracts were then concentrated and analysed directly by GC/MS. Separation was accomplished on a methylsilicone capillary column (30 m x 0.32 mm i.d.). GC/MS was carried out under positive ion ammonia CI conditions, with selected ion monitoring of the [M + H]+ ions (m/z = 262 and 248) for CGS 18102A and CGS 18416A, respectively. The method was successively applied to the analysis of clinical samples from an ascending multidose safety and tolerability study conducted in six normal healthy male volunteers.
Drug Development Department, CIBA-GEIGY Corporation, Ardsley, NY 10502.
M
M
Leal
M J
MJ
Hayes
M L
ML
Powell
D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000097:blood* / Q000493:pharmacokinetics; D001578:Benzopyrans / Q000097:blood* / Q000493:pharmacokinetics; D004355:Drug Stability; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods* / Q000592:standards / Q000706:statistics & numerical data; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000097:blood* / Q000493:pharmacokinetics; D011786:Quality Control
D014151:Anti-Anxiety Agents; D001578:Benzopyrans; D010880:Piperidines; C067554:CGS 18102A